Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 12.00
NAS:SRNE's Cash-to-Debt is ranked lower than
57% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAS:SRNE: 12.00 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRNE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.34  Med: N/A Max: No Debt
Current: 12
Equity-to-Asset 0.29
NAS:SRNE's Equity-to-Asset is ranked lower than
82% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:SRNE: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRNE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.78 Max: 0.95
Current: 0.29
0.29
0.95
Piotroski F-Score: 4
Altman Z-Score: -0.89
Beneish M-Score: -0.26
WACC vs ROIC
18.80%
-534.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -1874.50
NAS:SRNE's Operating Margin % is ranked lower than
83% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NAS:SRNE: -1874.50 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRNE' s Operating Margin % Range Over the Past 10 Years
Min: -4710.43  Med: -869.56 Max: -265.3
Current: -1874.5
-4710.43
-265.3
Net Margin % -1324.35
NAS:SRNE's Net Margin % is ranked lower than
80% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NAS:SRNE: -1324.35 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRNE' s Net Margin % Range Over the Past 10 Years
Min: -4763.26  Med: -867.85 Max: -264.71
Current: -1324.35
-4763.26
-264.71
ROE % -59.57
NAS:SRNE's ROE % is ranked lower than
63% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NAS:SRNE: -59.57 )
Ranked among companies with meaningful ROE % only.
NAS:SRNE' s ROE % Range Over the Past 10 Years
Min: -93.12  Med: -60.03 Max: -36.09
Current: -59.57
-93.12
-36.09
ROA % -23.03
NAS:SRNE's ROA % is ranked higher than
58% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NAS:SRNE: -23.03 )
Ranked among companies with meaningful ROA % only.
NAS:SRNE' s ROA % Range Over the Past 10 Years
Min: -2463.64  Med: -53.01 Max: -18.89
Current: -23.03
-2463.64
-18.89
ROC (Joel Greenblatt) % -1010.18
NAS:SRNE's ROC (Joel Greenblatt) % is ranked lower than
60% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NAS:SRNE: -1010.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRNE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2613.7  Med: -1104.72 Max: -254.29
Current: -1010.18
-2613.7
-254.29
3-Year Revenue Growth Rate 34.50
NAS:SRNE's 3-Year Revenue Growth Rate is ranked higher than
82% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:SRNE: 34.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRNE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 39.2
Current: 34.5
0
39.2
3-Year EBITDA Growth Rate -12.90
NAS:SRNE's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:SRNE: -12.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRNE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26.4 Max: 272.9
Current: -12.9
0
272.9
3-Year EPS without NRI Growth Rate 43.50
NAS:SRNE's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:SRNE: 43.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRNE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 31.2 Max: 238.7
Current: 43.5
0
238.7
GuruFocus has detected 5 Warning Signs with Sorrento Therapeutics Inc $NAS:SRNE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRNE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

SRNE Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

SRNE Guru Trades in Q4 2015

Jim Simons 29,190 sh (New)
Paul Tudor Jones 44,709 sh (New)
» More
Q1 2016

SRNE Guru Trades in Q1 2016

Jim Simons 53,890 sh (+84.62%)
Paul Tudor Jones 35,500 sh (-20.60%)
» More
Q2 2016

SRNE Guru Trades in Q2 2016

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SRNE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 8731
Compare:NAS:PTGX, NAS:VBIV, NAS:MNKD, NAS:TRVN, NAS:CGEN, NAS:CYAD, NAS:SELB, NAS:PPHM, NAS:ENZY, NAS:STML, NAS:MNOV, NAS:FATE, NAS:GNMX, NAS:ABEO, NAS:CEMP, NAS:VTVT, NAS:FBIO, NAS:PETX, NAS:CASC, OTCPK:SPRWF » details
Traded in other countries:8STN.Germany,
Sorrento Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States.

Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.

Top Ranked Articles about Sorrento Therapeutics Inc

Insider Buys Shares of Sorrento Therapeutics Company CEO invests in 20,000 shares
Sorrento Therapeutics Inc. (SRNE) President and CEO Henry Ji (Insider Trades) purchased 20,000 shares of the company for $5.15 per share on Feb. 10. The total transaction amounted to $103,000. Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.03
SRNE's PB Ratio is ranked higher than
57% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SRNE: 3.03 )
Ranked among companies with meaningful PB Ratio only.
SRNE' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 4.7 Max: 225.52
Current: 3.03
1.31
225.52
PS Ratio 36.51
SRNE's PS Ratio is ranked lower than
70% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. SRNE: 36.51 )
Ranked among companies with meaningful PS Ratio only.
SRNE' s PS Ratio Range Over the Past 10 Years
Min: 26.64  Med: 92.86 Max: 7291.67
Current: 36.51
26.64
7291.67
Current Ratio 1.99
SRNE's Current Ratio is ranked lower than
75% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SRNE: 1.99 )
Ranked among companies with meaningful Current Ratio only.
SRNE' s Current Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.85 Max: 18.58
Current: 1.99
1.42
18.58
Quick Ratio 1.99
SRNE's Quick Ratio is ranked lower than
70% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SRNE: 1.99 )
Ranked among companies with meaningful Quick Ratio only.
SRNE' s Quick Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.85 Max: 18.58
Current: 1.99
1.42
18.58
Days Sales Outstanding 203.72
SRNE's Days Sales Outstanding is ranked lower than
90% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. SRNE: 203.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRNE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.09  Med: 100.66 Max: 312.63
Current: 203.72
42.09
312.63
Days Payable 315.11
SRNE's Days Payable is ranked higher than
88% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. SRNE: 315.11 )
Ranked among companies with meaningful Days Payable only.
SRNE' s Days Payable Range Over the Past 10 Years
Min: 250.63  Med: 295.86 Max: 196461.25
Current: 315.11
250.63
196461.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -46.60
SRNE's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SRNE: -46.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRNE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -569.4  Med: -85.6 Max: 0
Current: -46.6
-569.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 4.38
SRNE's Price-to-Tangible-Book is ranked higher than
50% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SRNE: 4.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRNE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.61  Med: 18.45 Max: 2031.25
Current: 4.38
2.61
2031.25
Price-to-Median-PS-Value 0.39
SRNE's Price-to-Median-PS-Value is ranked higher than
86% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. SRNE: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRNE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.98 Max: 78.13
Current: 0.39
0.37
78.13
Earnings Yield (Greenblatt) % -52.73
SRNE's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. SRNE: -52.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRNE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -57.15  Med: 1.5 Max: 1.8
Current: -52.73
-57.15
1.8

More Statistics

Revenue (TTM) (Mil) $5.47
EPS (TTM) $ -1.86
Beta2.06
Short Percentage of Float11.91%
52-Week Range $3.90 - 8.35
Shares Outstanding (Mil)50.89

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 5 5 5 5
EPS ($) -1.96 -1.04 -1.10 -1.30
EPS without NRI ($) -1.96 -1.04 -1.10 -1.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SRNE

Headlines

Articles On GuruFocus.com
Insider Buys Shares of Sorrento Therapeutics Feb 15 2017 

More From Other Websites
SORRENTO THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 22 2017
SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 21 2017
SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 20 2017
Sorrento and Wildcat Announce Resolution Mar 20 2017
Sorrento and Wildcat Announce Resolution Mar 20 2017
Sorrento Therapeutics to Present at 29th Annual ROTH Conference Mar 09 2017
Insider Buys Shares of Sorrento Therapeutics Feb 15 2017
The Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017... Jan 23 2017
SORRENTO THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Jan 20 2017
ETFs with exposure to Sorrento Therapeutics, Inc. : January 9, 2017 Jan 09 2017
Sorrento Therapeutics, Inc. – Value Analysis (NASDAQ:SRNE) : January 9, 2017 Jan 09 2017
Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union... Jan 09 2017
Sorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRNE-US :... Jan 06 2017
SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Jan 05 2017
These 5 Stocks Under $10 Could Make You a Lot of Money Dec 22 2016
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance Dec 21 2016
ETFs with exposure to Sorrento Therapeutics, Inc. : December 8, 2016 Dec 08 2016
Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence... Dec 05 2016
Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for... Dec 01 2016
Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for... Dec 01 2016
SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 29 2016
Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility Nov 28 2016
ETFs with exposure to Sorrento Therapeutics, Inc. : November 23, 2016 Nov 23 2016
Sorrento Therapeutics to Attend Jefferies and ROTH Investor Conferences Nov 14 2016
Sorrento Therapeutics Closes Acquisition of Scilex Nov 08 2016
ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major... Sep 27 2016
Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and... Sep 13 2016
Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City Aug 30 2016
Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur... Aug 15 2016
Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc. Aug 09 2016
Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals... Aug 08 2016
Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell... Aug 02 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors Aug 01 2016
Sorrento Closes $150 Million Private Placement Investments Jun 08 2016
Sorrento and 3SBio Announce CAR-T Joint Venture in China Jun 07 2016
Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference May 26 2016
Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE... May 16 2016
Sorrento Therapeutics engaged advisors for exploring strategic alternatives May 09 2016
Sorrento closes private placement with Yuhan Corporation May 02 2016
Sorrento to Present at 2 Upcoming Conferences in New York City May 02 2016
Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting Apr 14 2016
Sorrento to Present at the Jefferies Immuno-Oncology Summit Apr 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)